VENOUS THROMBOEMBOLISM AND COMBINED ORAL CONTRACEPTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data obtained in a number of investigations identifying the risk of venous thromboembolism associated with the use to combined oral contraceptives in reproductive-aged and premenopausal women. Materials and methods. The systematic review included the data of foreign and Russian papers published in PubMed and Medline in the past 10 years. Results. The paper describes the mechanisms for venous thromboembolism and outlines the concepts determining the negative effects of hormonal contraceptives on the hemostatic system. Conclusion. When prescribing combined oral contraceptives, it is necessary to individually assess the relative and absolute risk factors of venous and arterial thromboses, including premorbid diseases. Molecular genetic studies offer wide prospects to identify patients who are prone to thrombophilia.

Full Text

Restricted Access

About the authors

Oksana Vladimirovna Yakushevskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: ykushox83@mail.ru
PhD, researcher, Department of gynecological endocrinology Moscow 117997, Ac. Oparina str. 4, Russia

Svetlana Vladimirovna Yureneva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com About the authors:
MD, PhD, leading researcher, Department of gynecological endocrinology Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Прилепская В.Н. Гормональная контрацепция. Акушерство и гинекология. 1991; 12: 63.
  2. Дремова Н.Б., Холодова Е.В. Современный рынок контрацептивных средств: маркетинговый анализ. Маркетинг в России и за рубежом. 2004; 6: 30-9.
  3. Макацария А.Д., ред. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей. М.: МИА; 2011.
  4. Farmer R.D., Lawrenson R.A., Thompson C.R. Population-based study of risk of venous thromboembolism associated with various oral eontraceptives. Lancet.1997; 349(9045): 83-8.
  5. Lidegaard Ø., Lokkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339: b2890.
  6. Lowe G.D. Virchow’s triad revisited: abnormal flow. Pathophysiol. Haemost. Thromb. 2004; 33(5-6): 455-7.
  7. Kemmeren J.M., Algra A., Meijers J.C., Tans G., Bouma B.N., Curvers J. et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood. 2004; 103(3): 927-33.
  8. Rosendaal F.R. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am. Soc. Hematol. Educ. Program. 2005: 1-12.
  9. Pinter B. Continuation and compliance of contraceptive use. Eur. J. Contracept. Reprod. Health Care. 2002; 7(3): 178-83.
  10. Spencer F.A., Emery C., Lessard D., Anderson F., Emani S., Aragam J. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med. 2006; 21(7): 722-7.
  11. Nightingale A.L., Lawrenson R.A., Simpson E.L., Williams T.J., MacRae K.D., Farmer R.D. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care. 2000; 5(4): 265-77.
  12. van Vlijmen E.F., Brouwer J.L., Veeger N.J., Eskes T.K., de Graeff P.A., van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch. Intern. Med. 2007; 167(3): 282-9.
  13. Vandenbroucke J.P., Koster T., Briët E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994; 344(8935): 1453-7.
  14. Chang J., Elam-Evans L.D., Berg C.J., Herndon J., Flowers L., Seed K.A., Syverson C.J. Pregnancy-related mortality surveillance--United States, 1991-1999. MMWR Surveill. Summ. 2003; 52(2): 1-8.
  15. Cheng Y.J., Liu Z.H., Yao F.J., Zeng W.T., Zheng D.D., Dong Y.G., Wu S.H. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013; 10(9): e1001515.
  16. Pomp E.R., Rosendaal F.R., Doggen C.J. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am. J. Hematol. 2008; 83(2): 97-102.
  17. Heinemann L.A., Dinger J.C. Range of published estimates of vеnous thromboembolism incidence in young women. Contraception. 2007; 75(5): 328-36.
  18. Suissa S., Spitzer W.O., Rainville B., Cusson J., Lewis M., Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum. Reprod. 2000; 15(4): 817-21.
  19. Royal Coolege of General Practioners. Oral contraception and thromboembolic disease. J. Roy. Coll. Gen. Pract. 1967; 13(3): 267-79.
  20. Sartwell P.E., Masi A.T., Arthers F.G., Greene G.R., Smith H.E. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am. J. Epidemiol. 1969; 90(5): 365-80.
  21. Koster T., Small R.A., Rosendaal F.R., Helmerhorst F.M. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J. Intern. Med. 1995; 238(1): 31-7.
  22. Goebelsmann U., Mashchak C.A., Mishell D.R. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am. J. Obstet. Gynecol. 1985; 151(7): 868-77.
  23. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
  24. Alhenc-GelasM., Plu-Bureau G., Guillonneau S., Kirzin J.M., Aiach M., Ochat N., Scarabin P.Y. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J. Thromb. Haemost. 2004; 2(9): 1594-600.
  25. Rosing J., Tans G., Nicolaes G.A., Thomassen M.C., van Oerle R., van der Ploeg P.M. et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br. J. Haematol. 1997; 97(1): 233-8.
  26. Seaman H.E., de Vries C.S., Farmer R.D. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum. Reprod. 2003; 18(3): 522-6.
  27. FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ UCM 277384.pdf)
  28. Dinger J.C., Heinemann L.A. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007; 75(5): 344-54.
  29. Seeger J.D., Loughlin J., Eng P.M. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet. Gynecol. 2007; 110(3): 587-93.
  30. Dinger J.C., Bardenheuer K., Assmann A. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study). BMC Med. Res. Methodol. 2009; 9: 77.
  31. Dinger J., Assmann A., Moehner S. Long-term active surveillance study for oral contraceptives (LASS): impact of oral contraceptive use on the start of antihypertensive treatment. Pharmacoepidemiol. Drug Saf. 2010; 19: S232.
  32. Lidegaard Q., Hougaard N.L., Skovlund C.W., Skjeldestad F.E., Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011; 343: d6423.
  33. Jick S.S., Hernandez R.K. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011; 342: d2151.
  34. Bayer HealthCare Pharmaceuticals Inc. US Prescribing Information; July 2011. Available at: http: //berlex.bayerhealthcare.com [accessed 8 AugUSt 2011]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies